About Inmedix
Inmedix, Inc. makes CloudHRV, a diagnostic that medical caregivers use in the clinic to measure heart rate variability. A patient lies at rest for about five minutes while the system records ECG data. The data go to a cloud service that Inmedix hosts, where proprietary algorithms calculate the results. The report covers two parts of autonomic nervous system control: the rest-and-restore side and the fight-or-flight side. The FDA cleared the system in January 2025.
Inmedix is based in Normandy Park, Washington, and has a UK subsidiary, Inmedix UK, Ltd. Andrew J. Holman, a rheumatologist, founded the company with Tim Sciarrillo and is its president and chief executive officer. Steven Daly is chief operating officer. Bernie Tobin, a former president of Crescendo Bioscience, is an independent member of the board of directors. CloudHRV passed 1000 procedures in its first five months and launched nationwide in August 2026. A charity golf event has raised more than $250,000 over 10 years for pediatric rheumatology at Seattle Children's.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 24, 2025 | Oct 6, 2025amended Oct 22, 2026 | $4,009,945of $5.0M target | 34 | $117K | DebtRule 506(c) | Form D/A ↗1 earlier filing |
| Aug 23, 2024 | Nov 1, 2024 | $720,000of $3.5M target | 5 | $144K | EquityRule 506(c) | Form D ↗ |
| Apr 14, 2023 | Apr 25, 2023 | $25,000of $3.0M target | 0 | — | OptionsRule 506(c) | Form D ↗ |
| Mar 17, 2022 | Mar 30, 2022 | $445,000of $3.0M target | 6 | $74,167 | Equity, OptionsRule 506(b) | Form D ↗ |
| Mar 3, 2021 | Mar 18, 2021 | $470,000of $2.0M target | 8 | $58,750 | DebtRule 506(b) | Form D ↗ |
| Total, five offerings | $5,669,945 | |||||
The filing for the offering first filed Apr 25, 2023 reports amount sold with no investors. Figures are shown as filed.
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by Inmedix
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| May 30, 2024 | Bridge convertible note | $4 million | Angel investors | Inmedix press release, May 30, 2024 ↗ Inmedix news list ↗ |
Why Investors Backed Inmedix
Inmedix sells CloudHRV, a diagnostic that measures heart rate variability in the clinic. It began as a patent holding company and later became a diagnostic and therapeutic company. The FDA cleared CloudHRV in January 2025. In May 2024, Inmedix completed a $4 million bridge convertible note round with angel investors.
The problem it targets
Inmedix argued in July 2020 that stress strongly affects how active autoimmune disease is and how patients respond to treatment. It added that remission rates stayed near 25% for 20 years, with no alternative approach in sight. It also set out to measure what blood tests cannot. It wanted to avoid the delays and overhead of traditional clinical laboratories. The first targets were rheumatoid arthritis, psoriatic arthritis, lupus and ankylosing spondylitis in adults.
What the product does
CloudHRV gives results in the clinic within 10 to 15 seconds, because the calculations run in the cloud. The FDA cleared it to measure heart rate variability in adults age 22 or older with normal sinus rhythm. Its 510(k) summary compares it with the DyAnsys ANSiscope system and concludes it is as safe and effective as that predicate. Inmedix plans to study CloudHRV and autonomic nervous system neuromodulation in clinical trials. It also plans to expand access worldwide.
Progress so far
A July 2025 release placed CloudHRV in a Johns Hopkins Lyme disease clinic. In March 2026, Fitt/Insider named Inmedix one of 50 early-stage health and wellness startups. In January 2024, the company appointed Nathan Smith as CFO and Lucy Lu as CCO. Much earlier, in 2007, Inmedix sold an international patent portfolio to Boehringer-Ingelheim for $10,000,000.
Who backs it
In May 2024, Inmedix completed a $4 million bridge convertible note round with angel investors. Stuart Hwang, who works on corporate development, is also an investor. Keiretsu Forum investor expos recognized Inmedix as a Most Valued Company in 2020 and 2021. At the spring 2025 expo for the Pacific Northwest and Rockies, it ranked first. Bernie Tobin, a former president of Crescendo Bioscience, joined the board in July 2020. Leroy Hood and Kevin Tracey joined the board later.
We wrote this summary from public statements by Inmedix and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Inmedix's Form D filed Oct 22, 2026.
Earlier filings also listed Steven Daly (director, last listed Mar 2022) and Andrew Holman (ceo & president, director, last listed Mar 2022).
Sources
- SECInmedix, Inc. Form D, filed Oct 6, 2025
- SECInmedix, Inc. filing history
- CompanyInmedix company overview
- CompanyInmedix team page
- CompanyInmedix contact page
- CompanyInmedix investor relations page
- CompanyInmedix release: $250,000 over 10 years for Seattle Children's
- CompanyInmedix release: CloudHRV nationwide launch
- PressInmedix welcomes Bernie Tobin to its Board of Directors (EIN Presswire, July 15, 2020)
- ResearchFDA 510(k) summary K241217 for CloudHRV System